Michael Barbella, Managing Editor05.03.24
Scottish impact investor Eos Advisory and a consortium that includes some U.S.-based financiers are providing Neupulse with $3.2 million in seed stage funding to advance the company's Tourettes Syndrome (TS) treatment.
Neupulse is touting its solution as the first wearable device to tackle TS and other tic disorders through mild electrical stimulation. A working prototype of the product stimulates the wrist's median nerve to reduce tic frequency; clinical trials conducted last year showed the device can reduce tics by more than 25%.
“Tourettes Syndrome is a debilitating condition, severely so in many cases and to the detriment of quality of life, and our mission is to drastically reduce tics with an easy-to-use wearable device that will be transformative to the lives of affected individuals," Neupulse CEO Paul Cable said. "Our device is an alternative to the current provision of treatment for TS, which is centred around medication and cognitive behaviour therapy. The goal is for Neupulse to be available to the TS community globally in the years ahead.”
Affecting up to 2% of the world's pediatric population and 1% of the planet's overall population, TS is characterized by involuntary, repetitive movements and vocalizations known as tics. The causes of this neurological condition and other tic disorders remain unclear, but genetic and environmental factors are known to play a role. TS can cause significant pain and discomfort for those affected, through the hundreds of daily involuntary and often violent motions, in addition to impacting social integration in education, work, and wider society.
“Eos was set up to back science-based companies and founders developing technologies that can positively impact the lives of people across the globe. Whilst we are focussed on Scottish startups, when one of our investors brought the amazing work of Neupulse to our attention we realised that there was a huge opportunity to add value, well beyond the investment, to help bring this device to market and improve the lives of people affected by TS and related conditions," Eos Advisory Partner Ana Stewart stated. "What’s even more exciting is how the technology could be beneficial for many other neural conditions in the future.”
Neupulse is the trading name for Neurotherapeutics Ltd., which was founded as a spinout from the University of Nottingham in 2021.
Neupulse is touting its solution as the first wearable device to tackle TS and other tic disorders through mild electrical stimulation. A working prototype of the product stimulates the wrist's median nerve to reduce tic frequency; clinical trials conducted last year showed the device can reduce tics by more than 25%.
“Tourettes Syndrome is a debilitating condition, severely so in many cases and to the detriment of quality of life, and our mission is to drastically reduce tics with an easy-to-use wearable device that will be transformative to the lives of affected individuals," Neupulse CEO Paul Cable said. "Our device is an alternative to the current provision of treatment for TS, which is centred around medication and cognitive behaviour therapy. The goal is for Neupulse to be available to the TS community globally in the years ahead.”
Affecting up to 2% of the world's pediatric population and 1% of the planet's overall population, TS is characterized by involuntary, repetitive movements and vocalizations known as tics. The causes of this neurological condition and other tic disorders remain unclear, but genetic and environmental factors are known to play a role. TS can cause significant pain and discomfort for those affected, through the hundreds of daily involuntary and often violent motions, in addition to impacting social integration in education, work, and wider society.
“Eos was set up to back science-based companies and founders developing technologies that can positively impact the lives of people across the globe. Whilst we are focussed on Scottish startups, when one of our investors brought the amazing work of Neupulse to our attention we realised that there was a huge opportunity to add value, well beyond the investment, to help bring this device to market and improve the lives of people affected by TS and related conditions," Eos Advisory Partner Ana Stewart stated. "What’s even more exciting is how the technology could be beneficial for many other neural conditions in the future.”
Neupulse is the trading name for Neurotherapeutics Ltd., which was founded as a spinout from the University of Nottingham in 2021.